Liposomal bupivacaine, nerve blocks compared to lidocaine for skin graft donor site pain in burn patients

Status: COMPLETED | Phase: PHASE4 Condition(s): Pain, Postoperative, Burns Intervention(s): Lidocaine Hydrochloride (DRUG), Liposomal bupivacaine (DRUG), Bupivacaine Hydrochloride (DRUG) Donor site pain study comparing post-operative donor site pain and opioid consumption after use of Lidocaine, Liposomal Bupivicaine or regional nerve block for split thickness skin graft harvesting in patients with less than 20% TBSA burn wounds and less than %5 Deep partial or full thickness burn wounds. Detailed: The first phase of the study was a randomized controlled study. In the second phase, all subjects will receive fascia iliaca, lateral femoral cutaneous, or femoral nerve blocks based on the proposed donor site location and will be compared to historic controls from the first phase. In the first phase, the control group underwent split thickness autografting using the standard protocol, involving injection of lidocaine with epinephrine at the donor site. In the first phase, the experimental group underwent injection of liposomal bupivacaine (Exparel) at the time of harvest of the skin graft. In the second phase, patients will undergo preoperative regional anesthesia with a fascia iliaca, lateral femoral cutaneous, or femoral nerve block based on the proposed donor site location rather than Primary Outcome(s): A Measurement of Post Operative Pain Involving Skin Graft Donor Site Using Visual Analog Scale (VAS) Ranging 0-10, at 8 Hours Post-operatively Enrollment: 74 (ACTUAL) Lead Sponsor: University of Kansas Medical Center Start: 2019-03-18 | Primary Completion: 2025-08-06 Results posted: 2026-03-31